169 related articles for article (PubMed ID: 24718278)
1. A possible role for NKT-like cells in patients with chronic hepatitis B during telbivudine treatment.
Diao H; He J; Zheng Q; Chen J; Cui G; Wei Y; Ye P; Kohanawa M; Li L
Immunol Lett; 2014 Jul; 160(1):65-71. PubMed ID: 24718278
[TBL] [Abstract][Full Text] [Related]
2. Restored circulating invariant NKT cells are associated with viral control in patients with chronic hepatitis B.
Jiang X; Zhang M; Lai Q; Huang X; Li Y; Sun J; Abbott WG; Ma S; Hou J
PLoS One; 2011; 6(12):e28871. PubMed ID: 22194934
[TBL] [Abstract][Full Text] [Related]
3. Enhanced functions of peripheral γδ T cells in chronic hepatitis B infection during interferon α treatment in vivo and in vitro.
Chen M; Hu P; Ling N; Peng H; Lei Y; Hu H; Zhang D; Ren H
PLoS One; 2015; 10(3):e0120086. PubMed ID: 25774808
[TBL] [Abstract][Full Text] [Related]
4. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.
Ma L; Cai YJ; Yu L; Feng JY; Wang J; Li C; Niu JQ; Jiang YF
Antimicrob Agents Chemother; 2013 Mar; 57(3):1304-11. PubMed ID: 23274669
[TBL] [Abstract][Full Text] [Related]
5. Kinetics of Th17 cytokines during telbivudine therapy in patients with chronic hepatitis B.
Hao C; Wang J; Kang W; Xie Y; Zhou Y; Ma L; Peng M; Bai X; Lian J; Jia Z
Viral Immunol; 2013 Oct; 26(5):336-42. PubMed ID: 24028690
[TBL] [Abstract][Full Text] [Related]
6. Functional restoration of CD56
Chen T; Zhu L; Shi A; Ding L; Zhang X; Tan Z; Guo W; Yan W; Han M; Jia J; Luo X; Schuppan D; Ning Q
Hepatol Int; 2017 Sep; 11(5):419-428. PubMed ID: 28639033
[TBL] [Abstract][Full Text] [Related]
7. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment.
Li C; Ji H; Cai Y; Ayana DA; Lv P; Liu M; Jiang Y
J Interferon Cytokine Res; 2013 Oct; 33(10):612-8. PubMed ID: 23697556
[TBL] [Abstract][Full Text] [Related]
8. Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection.
Ghosh S; Nandi M; Pal S; Mukhopadhyay D; Chakraborty BC; Khatun M; Bhowmick D; Mondal RK; Das S; Das K; Ghosh R; Banerjee S; Santra A; Chatterjee M; Chowdhury A; Datta S
Clin Microbiol Infect; 2016 Aug; 22(8):733.e9-733.e19. PubMed ID: 27208430
[TBL] [Abstract][Full Text] [Related]
9. Aberrant expression and dysfunction of TLR2 and its soluble form in chronic HBV infection and its regulation by antiviral therapy.
Huang Z; Ge J; Pang J; Liu H; Chen J; Liao B; Huang X; Zuo D; Sun J; Lu M; Zhang X; Hou J
Antiviral Res; 2015 Jun; 118():10-9. PubMed ID: 25771704
[TBL] [Abstract][Full Text] [Related]
10. Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127low T cells in parallel with inhibiting hepatitis B virus DNA.
Yan Z; Zhou J; Zhang M; Fu X; Wu Y; Wang Y
Mol Med Rep; 2014 May; 9(5):2024-30. PubMed ID: 24626572
[TBL] [Abstract][Full Text] [Related]
11. Tim-3 expression on peripheral monocytes and CD3+CD16/CD56+natural killer-like T cells in patients with chronic hepatitis B.
Rong YH; Wan ZH; Song H; Li YL; Zhu B; Zang H; Zhao Y; Liu HL; Zhang AM; Xiao L; Xin SJ; You SL
Tissue Antigens; 2014 Feb; 83(2):76-81. PubMed ID: 24397461
[TBL] [Abstract][Full Text] [Related]
12. Relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B patients receiving telbivudine antiviral treatment: A longitudinal observational study.
Yang X; Li J; Liu J; Gao M; Zhou L; Lu W
Medicine (Baltimore); 2017 Jun; 96(23):e7064. PubMed ID: 28591041
[TBL] [Abstract][Full Text] [Related]
13. Association among cytokine profiles of innate and adaptive immune responses and clinical-virological features in untreated patients with chronic hepatitis B.
Gu Y; Lian Y; Zheng Q; Huang Z; Gu L; Bi Y; Li J; Huang Y; Wu Y; Chen L; Huang Y
BMC Infect Dis; 2020 Jul; 20(1):509. PubMed ID: 32664850
[TBL] [Abstract][Full Text] [Related]
14. Rapid downregulation of programmed death-1 and interferon-γ-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B.
Hou FQ; Wu XJ; Wang Y; Chen J; Liu YZ; Ren YY; Song G; Ding YP; Yu M; Wang GQ
J Viral Hepat; 2013 Apr; 20 Suppl 1():18-26. PubMed ID: 23458521
[TBL] [Abstract][Full Text] [Related]
15. The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection.
Li M; Zhou ZH; Sun XH; Zhang X; Zhu XJ; Jin SG; Jiang Y; Gao YT; Li CZ; Gao YQ
Hepatol Int; 2016 Jul; 10(4):594-601. PubMed ID: 26924524
[TBL] [Abstract][Full Text] [Related]
16. Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment.
Lv G; Ying L; Ma WJ; Jin X; Zheng L; Li L; Yang Y
Virol J; 2010 Aug; 7():207. PubMed ID: 20807412
[TBL] [Abstract][Full Text] [Related]
17. TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in chronic hepatitis B.
Lai Q; Ma S; Ge J; Huang Z; Huang X; Jiang X; Li Y; Zhang M; Zhang X; Sun J; Abbott WG; Hou J
PLoS One; 2014; 9(2):e88475. PubMed ID: 24551107
[TBL] [Abstract][Full Text] [Related]
18. PD-1/PDL1 and CD28/CD80 pathways modulate natural killer T cell function to inhibit hepatitis B virus replication.
Wang XF; Lei Y; Chen M; Chen CB; Ren H; Shi TD
J Viral Hepat; 2013 Apr; 20 Suppl 1():27-39. PubMed ID: 23458522
[TBL] [Abstract][Full Text] [Related]
19. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
Chen Y; Li X; Ye B; Yang X; Wu W; Chen B; Pan X; Cao H; Li L
Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
[TBL] [Abstract][Full Text] [Related]
20. Elevated Hepatic CD1d Levels Coincide with Invariant NKT Cell Defects in Chronic Hepatitis B Virus Infection.
Tan X; Ding Y; Zhu P; Dou R; Liang Z; Yang D; Huang Z; Wang W; Wu X; Weng X
J Immunol; 2018 May; 200(10):3530-3538. PubMed ID: 29643189
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
